1 week Ago By ABMN Staff
Hologic, Inc. ( NASDAQ:HOLX – Free Report ) – Stock analysts at Zacks Research reduced their Q1 2025 earnings estimates for Hologic in a research report issued on Tuesday, December 31st. Zacks Research analyst R.
Department now forecasts that the medical equipment provider will post earnings of $1.01 per share for the quarter, down from their prior forecast of $1.02.
The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2025 earnings at $1.
06 EPS, FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.
14 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.63 EPS, Q1 2027 earnings at $1.
12 EPS and FY2027 earnings at $4.99 EPS. A number of other equities research analysts have also recently commented on the company.
Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Evercore ISI boosted their price objective on Hologic from $78.
00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. StockNews.
com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Mizuho reduced their price objective on shares of Hologic from $90.00 to $87.
00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Finally, Leerink Partners dropped their target price on shares of Hologic from $95.00 to $90.
00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $89.
50. Hologic Stock Performance HOLX opened at $71.74 on Friday.
The firm has a fifty day moving average price of $76.87 and a 200 day moving average price of $78.43.
Hologic has a 1 year low of $70.36 and a 1 year high of $84.67.
The stock has a market cap of $16.28 billion, a P/E ratio of 21.54, a P/E/G ratio of 2.
32 and a beta of 0.96. The company has a debt-to-equity ratio of 0.
49, a current ratio of 3.69 and a quick ratio of 3.03.
Hologic ( NASDAQ:HOLX – Get Free Report ) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.
01. Hologic had a return on equity of 19.79% and a net margin of 19.
59%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.
25 million. During the same quarter in the prior year, the business earned $0.89 earnings per share.
The company’s revenue was up 4.5% compared to the same quarter last year. Institutional Trading of Hologic Several institutional investors and hedge funds have recently bought and sold shares of HOLX.
State Street Corp boosted its position in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after buying an additional 81,057 shares during the period.
FMR LLC raised its holdings in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter.
The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after purchasing an additional 18,774 shares in the last quarter.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Hologic by 8.
6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.
now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after buying an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. raised its stake in Hologic by 60.
9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares in the last quarter.
94.73% of the stock is currently owned by hedge funds and other institutional investors. Insider Buying and Selling In related news, COO Essex D.
Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.
04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38.
This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link .
1.75% of the stock is currently owned by company insiders. Hologic Company Profile ( Get Free Report ) Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. See Also Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.
com's FREE daily email newsletter ..
